3 days popular7 days popular1 month popular3 months popular

Ebola vaccine: Promising phase I trials

“The results for tolerability, safety, and the immune response to the vaccine candidate are very promising,” explains Prof Marylyn Addo. The antibodies which developed against the virus were still detectable after six months. Addo is convinced, “With this, a single vaccine could provide lasting protection against Ebola.” The infectious disease specialist, who works for the German Center for Infection Research at the University Medical Center Hamburg Eppendorf (UKE) in Hamburg, led the trial in Hamburg. A total of 158 healthy adult volunteers were tested in Hamburg, as well as at the partner sites in Geneva (Switzerland), Lambaréné; (Gabon) and Kilifi (Kenya).

Ebola Virus
This is a colorized transmission electron micrograph (TEM) revealing some of the ultrastructural morphology displayed by an Ebola virus virion.
Credit: cdc/Frederick Murphy